Loss of OBSCN expression promotes bladder cancer progression but enhances the efficacy of PD-L1 inhibitors
{{output}}
Background: As the objective overall response rate to immune checkpoint inhibitors (ICIs) is less than 30% in late stage or metastatic bladder cancer (BLCA), elucidating the intrinsic mechanisms of immune evasion is of great impo... ...
